May 2024 in “International Journal of Nanomedicine” Biodegradable polymers can improve cannabinoid delivery but need more clinical trials.
4 citations,
January 2023 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
1 citations,
July 2022 in “JEADV Clinical Practice” New and existing treatments for hair loss show promise, with some being more effective for men and others for women.
15 citations,
January 2022 in “Immune Network/Immune network” New targeted immunotherapies are improving treatment for inflammatory skin diseases.
4 citations,
September 2012 in “Clinical Pharmacology in Drug Development” Different drug doses approved in Japan and the U.S. are not mainly due to different clinical responses, and ethnic factors should be considered in setting drug doses.
1 citations,
June 2017 in “International Journal of Toxicology” Most drugs fail to reach the market, but understanding their properties and using strategies like early toxicity tests and drug repurposing can help advance their development.
56 citations,
January 2021 in “Clinical and Experimental Medicine” The document concludes that while there are various treatments for Alopecia Areata, there is no cure, and individualized treatment plans are essential due to varying effectiveness.
20 citations,
January 2000 in “Dermatologic Clinics” New psoriasis treatments are effective but come with side effects and risks.
8 citations,
February 2019 in “Journal of The European Academy of Dermatology and Venereology” 3 citations,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
76 citations,
February 2021 in “International Journal of Molecular Sciences” Mesenchymal stem cells show potential for skin healing and anti-aging, but more research is needed for safe use, especially regarding stem cells from induced pluripotent sources.
66 citations,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
59 citations,
June 2022 in “Frontiers in medicine” There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.
51 citations,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
25 citations,
July 2013 in “Actas Dermo-Sifiliográficas” Acitretin is effective for severe psoriasis and can be used long-term due to no immunosuppression, but must be carefully monitored for side effects and is not for pregnant women.
1 citations,
June 2021 in “Journal of dermatology and dermatitis” Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.
1 citations,
April 2019 in “Journal of Investigative Dermatology” VB1953 gel significantly reduced acne and resistant bacteria in patients who didn't respond to clindamycin.
April 2024 in “Frontiers in medicine” Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.
June 2023 in “Dermatology and therapy” Doctors in the Middle East need better treatments and more knowledge about new therapies for hair loss condition Alopecia Areata.
April 2019 in “Journal of Investigative Dermatology” Many patients with autoimmune blistering skin disorders change their diets, avoiding foods like alcohol, citrus, and spices, and some find vegetables and dairy helpful.
61 citations,
June 2022 in “Journal of Controlled Release” Dissolving microneedles show promise for delivering medication through the skin but face challenges like manufacturing complexity and regulatory hurdles.
April 2024 in “Journal of translational medicine” MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.
3 citations,
July 2023 in “International journal of molecular sciences” Stress may contribute to hair loss in alopecia areata by affecting immune responses and cell death in hair follicles.
October 2022 in “Cosmoderma” 55 citations,
October 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.
49 citations,
November 2021 in “Annual review of pathology” Lysophospholipids like LPA and S1P are important for hair growth, immune responses, and vascular development, and could be targeted for treating diseases.
21 citations,
May 2017 in “Paediatric drugs” Individualized treatment plans are crucial for children with alopecia areata, with promising options like JAK inhibitors showing significant hair regrowth.
16 citations,
March 2022 in “Archives of Toxicology” Botulinum and tetanus neurotoxins are better understood now, with updated information on their effects and treatment.
2 citations,
September 2019 in “Springer eBooks” 1 citations,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The summit concluded that new treatments like Jak inhibitors show promise for Alopecia Areata and personalized approaches are needed.